Skip to main content

BETR · BetterLife Pharma Inc. · Financials

0.2250 CAD +0.0050 (+2.27%) At close · Nov 6 Intraday price with Plus

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Diluted EPS
-$1.10 -10%
FY2016 Diluted EPS FY2015–FY2016

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
— — — — — — — — — — — $430.32K $1.78M -$2.88M
CAD -2.9M -9.37M -11.99M -36.35M -19.59M — — — — — — — — —
USD/shares — — — — — — — — -$1.10 -$1.00 — — — —
USD/shares — — — — — — — — -$1.10 -$1.00 — — — —
shares — — — — — 9.02M 7.99M 7.53M 7.77M 1.16M 482.87K 3.58M 3.39M 2.8M
shares — — — — — 9.02M 7.99M 7.53M 7.77M — — — — —
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current portion of long-term borrowings 2024-01-31 CAD 50,052 20-F filed 2025-06-02
Noncurrent long-term borrowings 2024-01-31 CAD 49,115 20-F filed 2025-06-02
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.